Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.
While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to Dr. Quigley, who addresses the importance of identifying and reducing residual inflammatory risk.
E-Cigarettes and Vaping: Another Cardiovascular Threat in Disguise? pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.